$4.990
+0.435 (+8.71%)Al cierre
Noticias de RXST
Eventos de RXST
RxSight Nearly Doubles Sales Force, Completes Organizational Restructuring
RxSight says nearly doubling sales force, completed organizational restructuring
RxSight Reports Q3 Revenue of $24.59M, Below Consensus
Reports Q3 revenue $24.59M, consensus $27.14M. "Since I joined last quarter, the team has moved quickly and accomplished a great deal in a short period of time," said Aziz Mottiwala, President and Chief Executive Officer of RxSight. "We have strengthened our commercial organization and leadership, made progress across key long-term growth initiatives, and taken decisive actions to align our cost structure with our priorities. While there is more work ahead, we remain focused on execution. Based on our progress, I am confident we are positioning our company for long-term success."
RxSight Withdraws 2026 Guidance
In connection with the leadership transition, RxSight announced Wednesday that it withdrew 2026 guidance and will resume formal guidance in early 2027.
RxSight Reports Q2 Revenue of $33.74M, Exceeding Expectations
Reports Q2 revenue $33.74M, consensus $32.55M. "It is a privilege to join RxSight and to work alongside the talented team that pioneered an entirely new category in cataract surgery with the only commercially available IOL platform that enables physicians to adjust and personalize vision after surgery," said Aziz Mottiwala, President and Chief Executive Officer of RxSight. "The opportunity ahead is significant, and our immediate priority is to strengthen commercial execution, deepen adoption across our installed base and translate the value of adjustability into durable growth. To support those priorities, I have commenced a comprehensive review of the business. While underlying trends remain generally consistent with our prior expectations, withdrawing 2026 guidance gives us the flexibility to establish the right operating plan and focus our resources on the core business, our pipeline and the Alcon collaboration."
RxSight Appoints Aziz Mottiwala as New CEO
RxSight (RXST) announced a planned leadership transition effective July 20, with Aziz Mottiwala appointed president and CEO, succeeding Ron Kurtz, who will continue to serve as chief medical officer. Mottiwala most recently served as chief commercial officer at Tarsus Pharmaceuticals (TARS). In connection with this transition, Kurtz will resign from the board of directors, at which time Mottiwala will be appointed to the board. The company is not updating its previously communicated financial guidance in connection with this announcement.
Artículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.